1184940-46-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
(alphaS)-3,5-difluoro-alpha-hydroxybenzeneacetic acid 2-(2-ethyl-4-hydroxy-3-methylbenzoyl)hydrazide is utilized as a research compound for exploring its potential biological activities, such as anti-inflammatory, analgesic, or antipyretic properties. Its unique structure and pharmacological potential make it a valuable candidate for the development of new medications to address various health conditions.
In the pharmaceutical industry, (alphaS)-3,5-difluoro-alpha-hydroxybenzeneacetic acid 2-(2-ethyl-4-hydroxy-3-methylbenzoyl)hydrazide is used as a lead molecule for drug discovery, aiming to identify and optimize its therapeutic effects. The exploration of its properties can contribute to the advancement of treatments for inflammatory conditions, pain management, and fever reduction, among other applications. The complex structure of (alphaS)-3,5-difluoro-alpha-hydroxybenzeneacetic acid 2-(2-ethyl-4-hydroxy-3-methylbenzoyl)hydrazide provides a foundation for further chemical modifications and improvements to enhance its efficacy and safety profile in clinical settings.

Upstream product

• 1181770-76-2 2-ethyl-4-methoxy-3-methylbenzoic acid 
• 1181770-80-8 N'-[2-(3,5-difluorophenyl)-2-hydroxyacetyl]-2-ethyl-4-methoxy-3-methylbenzohydrazide 
• 1181770-72-8 EMD 638683 
• 5628-61-5 4-methoxy-2,3-dimethyl-benzoic acid 
• 38998-17-3 2,3-dimethyl-4-methoxybenzaldehyde 
• 208259-37-4 methyl 2-(3,5-difluorophenyl)-2-hydroxyacetate 
• 132741-31-2 S-(+)-3.5-Difluoromandelic Acid 

Relevant academic research and scientific papers

SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS

The present invention relates to a compound of the formula I, Ia and Ib, and its pharmaceutically usable tautomers, salts, stereoisomers and the enantiomers, including mixtures thereof in all ratios. The present invention furthermore also relates to compounds of the formula II for the prophylaxis and/or treatment of viral diseases and/or carcinomas, in which R1, R2 each, independently of one another, denote H, CHO or acetyl, R3, R4, R5, R6, R7, R8, R9, R10, R11 each, independently of one another, denote H, A, OSO2A, Hal, NO2, OR12, N(R12)2, CN, O—COA, —[C(R12)2]nCOOR12, O—[C(R12)2]oCOOR12, SO3H, —[C(R12)2]nAr, —CO—Ar, O—[C(R12)2]nAr, —[C(R12)2]nHet, —[C(R12)2]nC≡CH, O—[C(R12)2]nC≡CH, —[C(R12)2]nCON(R12)2, —[C(R12)2]nCONR12N(R12)2, O—[C(R12)2]nCON(R12)2, O—[C(R12)2]oCONR12N(R12)2, NR12COA, NR12CON(R12)2, NR12SO2A, N(SO2A)2, COR12, S(O)mAr, SO2NR12 or S(O)mA, R3 and R4 together also denote CH═CH—CH═CH, R3 and R4, R7 and R8 or R8 and R9 together also denote alkylene having 3, 4 or 5 C atoms, in which one or two CH2 groups may be replaced by oxygen, A denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F, or cyclic alkyl having 3-7 C atoms, Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR12, N(R12)2, NO2, CN, phenyl, CON(R12)2, NR12COA, NR12CON(R12)2, NR12SO2A, COR12, SO2N(R12)2, S(O)mA, —[C(R12)2]n—COOR12 and/or —O[C(R12)2]o—COOR12, Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by Hal, A; OR12, N(R12)2, NO2, CN, COOR12, CON(R12)2, NR12COA, NR12SO2A, COR12, SO2NR12, S(O)mA, ═S, ═NR12 and/or ═O (carbonyl oxygen), R12 denotes H or A, Ha1 denotes F, Cl, Br or I, m denotes O, 1 or 2, n denotes O, 1, 2 or 3, o denotes 1, 2 or 3, for the prophylaxis and/or treatment of viral diseases and/or carcinomas, and their pharmaceutically usable tautomers, salts, stereoisomers and the enantiomers, including mixtures thereof in all ratios.